Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Carlos Plata-Salamán"'
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The recent publication of the σ1R crystal structure is an important cornerstone for the derivation of more accurate activity prediction models. We report here a comparative study involving a set of more than 25,000 structures from our internal datab
Externí odkaz:
https://doaj.org/article/4c6a3fcb3bb14b6ebe2ca8941d885143
Autor:
Richard Langford, Adelaida Morte, Mariano Sust, Jesús Cebrecos, Anna Vaqué, Esther Ortiz, James Fettiplace, Shola Adeyemi, Grzegorz Raba, Liudmila But‐Husaim, Neus Gascón, Carlos Plata‐Salamán
Publikováno v:
European Journal of Pain. 26:2083-2096
STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal of tramadol-celecoxib (CTC)-a first-in-class analgesic co-crystal comprising racemic tramadol hydrochloride and celecoxib in a supramolecular netwo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d18c55b53ac28affc64ca914ab9fede
https://doi.org/10.1002/ejp.2021
https://doi.org/10.1002/ejp.2021
Autor:
Eugene R. Viscusi, Oscar de Leon‐Casasola, Jesús Cebrecos, Adam Jacobs, Adelaida Morte, Esther Ortiz, Mariano Sust, Anna Vaqué, Ira Gottlieb, Stephen Daniels, Joseph S. Gimbel, Derek Muse, Peter Winkle, Michael E. Kuss, Sebastián Videla, Neus Gascón, Carlos Plata‐Salamán
Publikováno v:
Pain practice : the official journal of World Institute of PainREFERENCES.
Celecoxib-tramadol co-crystal (CTC) is a first-in-class analgesic co-crystal of celecoxib and racemic tramadol with an improved pharmacologic profile, conferred by the co-crystal structure, compared with its active constituents administered alone/con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d52c331d4866bad70763dd1cfb83ddb5
https://pubmed.ncbi.nlm.nih.gov/35686380
https://pubmed.ncbi.nlm.nih.gov/35686380
Autor:
Artur Sans, Neus Gascón, Gregorio Encina, Eric Sicard, Lluis Soler, Carlos Plata-Salamán, Mariano Sust, Anna Vaqué, Mounia Lahjou, Sebastián Videla, Marisol Escriche
Publikováno v:
British Journal of Clinical Pharmacology. 84:64-78
SummaryAim We compared the pharmacokinetic (PK) profiles of Co-Crystal of Tramadol-Celecoxib (CTC) versus each reference product (alone and in open combination) after single (first dose) and multiple dosing. Methods Healthy adults aged 18–50 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a98e87ff0e992972a035175df3adff9
https://doi.org/10.1111/bcp.13428
https://doi.org/10.1111/bcp.13428
Autor:
Lluis Soler, Artur Sans, Mariano Sust, Sebastián Videla, Neus Gascón, Mounia Lahjou, Anna Vaqué, Carlos Plata-Salamán, Mercedes Encabo, Gregorio Encina, Eric Sicard
Publikováno v:
British Journal of Clinical Pharmacology
Aim Co-Crystal of Tramadol-Celecoxib (CTC) is a novel co-crystal molecule containing two active pharmaceutical ingredients (APIs) under development by Esteve (E-58425) and Mundipharma Research (MR308). This Phase I study compared single-dose pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13f18b5aa5bb25f33e755823b05d30c
https://doi.org/10.1111/bcp.13395
https://doi.org/10.1111/bcp.13395
Publikováno v:
Handbook of experimental pharmacology. 244
There is a critical need for new analgesics acting through new mechanisms of action, which could increase the efficacy respect to existing therapies and/or reduce their unwanted effects. Current preclinical evidence supports the modulatory role of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::773680c9d7f21ef82572cc7f2f560bd4
https://pubmed.ncbi.nlm.nih.gov/28275913
https://pubmed.ncbi.nlm.nih.gov/28275913